Revolutionizing healthcare one cell at a time.

IncellDx is a molecular diagnostics company dedicated to revolutionizing healthcare one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, we focus on critical life threatening diseases such as HIV/AIDs, HPV/Cervical Cancer, Hepatitis, organ transplant infections, breast cancer and ovarian cancer.

Our proprietary diagnostic method provides specific molecular details about each and every cell. This technology now made available through IncellDx, is capable of revolutionizing the field of molecular diagnostics, one cell at a time.

Learn More

New Product  -  Now Available
IncellDx launches new CMV mRNA Probe*.
*For Research Use Only. Not for use in diagnostic procedures.

HIV News
White paper on Simultaneous Ultrasensitive Subpopulation Staining/Hybridization In Situ (SUSHI) in HIV in Patients on HAART Therapy
Read more: http://www.hiv-reservoir.net/index.php/the-news/174-new-tool-for-hiv-reservoirs.html

IncellDx CEO Applauds New Cancer Screening Recommendations -Technology identifies cancer with more certainty than current tests

“I applaud the efforts of the USPSTF to drive revisions to outdated medical guidelines. I agree with the new guidelines and the need to reduce the number of false positives created by Pap and HPV tests. IncellDx is developing ’3Dx’ to address this concern.”
Read more: IncellDx CEO applauds new cervical cancer screening recommendations

Enzo Biochem Reaches Marketing Deal for IncellDx’s HPV Test

Enzo Biochem announced that its Enzo Clinical Labs subsidiary has reached an agreement with IncellDx for the rights to market a proprietary laboratory test. Upon receiving the appropriate approvals, Enzo will become the first New York licensed reference laboratory to offer the test.

Read more: Enzo Biochem Gets Rights to Potential HPV Test

IncellDx CEO Unveils Revolutionary New Technology In The Fight Against Cancer
‘Susan G Komen, Race For The Cure’ Applauds New Technology

IncellDx unveiled a new cancer screening technology that will detect certain cancers more accurately, more quickly, and less invasively than ever before. Patterson announced the new technology called ‘3Dx’ at Eurogin 2011.

Full Incell3Dx Press Release